Cumberland Pharmaceuticals Inc  (CPIX)
Other Ticker:  
Price: $1.6300 $-0.05 -2.976%
Day's High: $1.6447 Week Perf: -7.39 %
Day's Low: $ 1.63 30 Day Perf: -19.51 %
Volume (M): 1 52 Wk High: $ 2.36
Volume (M$): $ 2 52 Wk Avg: $1.80
Open: $1.63 52 Wk Low: $1.43

 Market Capitalization (Millions $) 23
 Shares Outstanding (Millions) 14
 Employees 96
 Revenues (TTM) (Millions $) 40
 Net Income (TTM) (Millions $) -6
 Cash Flow (TTM) (Millions $) -1
 Capital Exp. (TTM) (Millions $) 0

Cumberland Pharmaceuticals Inc
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company that is headquartered in Nashville, Tennessee. The company specializes in the development, marketing, and distribution of branded prescription products for the treatment of acute care, gastroenterology, oncology, pain management, and ophthalmology.

Cumberland Pharmaceuticals was founded in 1999 by A.J. Kazimi, who currently serves as the Chief Executive Officer of the company. Since its inception, the company has developed and launched multiple products in the market, including its flagship product, Acetadote, which is primarily used as an antidote to acetaminophen toxicity.

The company's product portfolio includes Caldolor, a non-steroidal anti-inflammatory drug used for pain management, Kristalose, a prescription laxative used for the treatment of constipation, Hepatoren, a prescription product used for the management of hepatic encephalopathy, and Ethyol, a product used to reduce certain side effects associated with chemotherapy and radiation.

Cumberland Pharmaceuticals has a robust research and development program that involves both internal research efforts and collaborations with other pharmaceutical companies and academic institutions. The company has also established distribution partnerships with some of the leading pharmaceutical companies in the world, including Merck, Sanofi, and Lupin.

The company operates in the United States and several international markets, including Europe, the Middle East, and Asia. In addition to its pharmaceutical business, Cumberland also has a medical products division that develops and markets medical accessories and devices used in the healthcare industry.

According to its latest financial reports, Cumberland Pharmaceuticals recorded sales of $99 million in 2020, up from $98 million in the previous year, and had a workforce of approximately 180 employees. The company has received several awards and recognitions for its innovation and contribution to the pharmaceutical industry, including being named one of the fastest-growing companies in the United States by Inc. Magazine.

   Company Address: 1600 West End Avenue Nashville 37203 TN
   Company Phone Number: 255-0068   Stock Exchange / Ticker: NASDAQ CPIX


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Cumberland Pharmaceuticals Inc

Cumberland Pharmaceuticals Inc. faces widening loss per share despite revenue growth in Q4 2023

The financial results for Cumberland Pharmaceuticals Inc for the October to December 31, 2023 fiscal span show a significant increase in loss per share compared to the same period a year prior. The loss per share widened to $-0.44 from $-0.17 in the previous year, and from $-0.07 in the previous reporting season. This represents a negative trend in the company's profitability.
On the revenue front, there was a slight growth of 2.514% to $9.35 million from $9.12 million in the comparable reporting season a year prior. However, sequentially, revenue deteriorated by -7.266% from $10.09 million. This fluctuation in revenue could indicate fluctuations in demand for Cumberland Pharmaceuticals Inc products.

Cumberland Pharmaceuticals Inc

Cumberland Pharmaceuticals Inc reports a significant revenue decline of -11.628%, signaling challenging times ahead amidst the fiscal year closing on September 30, 2023

Cumberland Pharmaceuticals Inc, a pharmaceutical company, recently released its financial results for the period closing September 30, 2023. The company reported a loss per share of $-0.07, compared to $-0.03 in the same period the previous year. Additionally, the earnings per share (EPS) fell from $0.06 in the previous reporting season.
One of the major concerns for the company was the substantial decline in revenue. The revenue dropped by -11.628% to $10.09 million, down from $11.41 million in the same reporting season a year before. Furthermore, the revenue deteriorated by -7.374% sequentially from $10.89 million. These figures reflect a challenging period for Cumberland Pharmaceuticals Inc, which may have been impacted by various factors such as market conditions and competition.

Cumberland Pharmaceuticals Inc

Cumberland Pharmaceuticals Inc Achieves Surprising Turnaround with Positive Second Quarter Results, Boasting 500% Increase in Earnings Per Share

Cumberland Pharmaceuticals Inc Reports Positive Second Quarter Results
In a surprising turn of events, Cumberland Pharmaceuticals Inc has announced positive financial results for the second quarter of 2023. The company's profits turned positive at $0.06 per share, compared to a loss of $0.09 per share in the same period a year ago. This marks a significant improvement, with earnings per share increasing by a staggering 500% from $0.01 per share in the previous financial reporting period.
One of the key drivers of this success is the growth in revenue. Cumberland Pharmaceuticals Inc experienced a 5.726% increase in revenue, reaching $10.89 million for the quarter. This is in stark contrast to the comparable financial reporting period a year ago, when revenue stood at $10.30 million. Moreover, the company's revenue also improved sequentially by 18.041% from $9.22 million. These figures are particularly noteworthy in an industry where most businesses are struggling with receding orders and diminishing revenue.

Cumberland Pharmaceuticals Inc

Cumberland Pharmaceuticals Inc Faces Economic Challenges with Decreasing Revenue per Employee in Q1 2023

Cumberland Pharmaceuticals Inc, a well-known name in the healthcare sector, has recently reported a significant fall in its revenue per employee. The trailing twelve months basis saw a drop to $417,297, but the company's productivity remains strong.
With a total of 96 employees, it is interesting to note that 138 other companies within the healthcare sector have achieved higher revenue per employee compared to Cumberland Pharmaceuticals Inc. The company's overall ranking has also deteriorated, dropping from 0 to 1457 compared to the fourth quarter of 2022.


Cumberland Pharmaceuticals Inc's Segments
• View Complete Report
  Company Estimates  
  Revenue Outlook
Cumberland Pharmaceuticals Inc does not provide revenue guidance.

Earnings Outlook
Cumberland Pharmaceuticals Inc does not provide earnings estimates.

Geographic Revenue Dispersion


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com